Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Janssen-Cilag | Barts & The London NHS Trust | St George's Healthcare NHS Trust | Bradford Teaching Hospitals NHS Foundation Trust | Nottingham University Hospitals NHS Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Telaprevir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 14, 2014
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Janssen-Cilag | Barts & The London NHS Trust | St George's Healthcare NHS Trust | Bradford Teaching Hospitals NHS Foundation Trust | Nottingham University Hospitals NHS Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1
Details : Telaprevir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis C, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 25, 2013
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Vertex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1
Details : Telaprevir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 02, 2013
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Vertex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Pharmacology Study of MP-424
Details : MP-424 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis C, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2013
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MP-424 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2012
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Toray Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MP-424 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2012
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Toray Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Janssen-Cilag
Deal Size : Inapplicable
Deal Type : Inapplicable
DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)
Details : Telaprevir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2012
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Janssen-Cilag
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Telaprevir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2012
Lead Product(s) : Telaprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telaprevir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Telaprevir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2012
Lead Product(s) : Telaprevir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telaprevir
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment
Details : Telaprevir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 17, 2012
Lead Product(s) : Telaprevir
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
